

Vanguard CPV suspension injectable pour chiens

Authorised

- Canine parvovirus, strain NL-35-D, Live

Product identification

Medicine name:

Vanguard CPV suspension injectable pour chiens

Vanguard CPV Injektionslösung

Active substance:

Canine parvovirus, strain NL-35-D, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine parvovirus, strain NL-35-D, Live

10000000.00 50% cell culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:

Suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AD01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Luxembourg

Available in:

Luxembourg

Package description:

Vanguard CPV 1 dose Vial Suspension for injection

Vanguard CPV 10 1 dose Vial Suspension for injection

Vanguard CPV 25 1 dose Vial Suspension for injection

Vanguard CPV 100 1 dose Vial Suspension for injection

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Belgium

Marketing authorisation date:

1/12/1993

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

Ministry Of Health And Social Security

Authorisation number:

V 087/93/11/0349

Date of authorisation status change:

10/10/2008

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.